Compare ResMed Inc. (RMD) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.89. The key difference: ResMed Inc. pays a 1.19% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and ResMed Inc. is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| RMD | USIG | |
|---|---|---|
Market Cap | $31.89B | — |
Sector | Health | Fixed Income |
52-Week High | $283.28 | $52.69 |
52-Week Low | $182.82 | $49.89 |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
USIG trades at $49.96, down 0.08% on the day, with technical indicators showing a bearish trend. Recent corporate actions include scheduled dividend payments in 2026. Institutional interest is evident from new stakes by Blue Edge Capital LLC and increased holdings by Bank of New York Mellon Corp, as reported by Defense World and Business Wire in July and August 2026.
The outlook remains cautious due to bearish technical signals and lack of recent fundamental data. Investment opportunities hinge on future financial disclosures and institutional support, while risks include market volatility and reliance on upcoming earnings for valuation clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
